JP7313345B2 - デング熱に対するブースターワクチン接種のための組成物 - Google Patents
デング熱に対するブースターワクチン接種のための組成物 Download PDFInfo
- Publication number
- JP7313345B2 JP7313345B2 JP2020519400A JP2020519400A JP7313345B2 JP 7313345 B2 JP7313345 B2 JP 7313345B2 JP 2020519400 A JP2020519400 A JP 2020519400A JP 2020519400 A JP2020519400 A JP 2020519400A JP 7313345 B2 JP7313345 B2 JP 7313345B2
- Authority
- JP
- Japan
- Prior art keywords
- dengue
- booster
- vaccination
- vaccine composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000025729 dengue disease Diseases 0.000 title claims description 414
- 206010012310 Dengue fever Diseases 0.000 title claims description 377
- 208000001490 Dengue Diseases 0.000 title claims description 344
- 238000002255 vaccination Methods 0.000 title claims description 168
- 239000000203 mixture Substances 0.000 title claims description 163
- 241000725619 Dengue virus Species 0.000 claims description 223
- 229960005486 vaccine Drugs 0.000 claims description 220
- 230000002238 attenuated effect Effects 0.000 claims description 76
- 239000000427 antigen Substances 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 230000003472 neutralizing effect Effects 0.000 claims description 71
- 208000009714 Severe Dengue Diseases 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 49
- 238000012360 testing method Methods 0.000 claims description 24
- 241000710831 Flavivirus Species 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 230000009467 reduction Effects 0.000 claims description 18
- 230000005875 antibody response Effects 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000006386 neutralization reaction Methods 0.000 claims description 12
- 241000710772 Yellow fever virus Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 229940051021 yellow-fever virus Drugs 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 description 62
- 239000007924 injection Substances 0.000 description 62
- 208000003152 Yellow Fever Diseases 0.000 description 59
- 241000700605 Viruses Species 0.000 description 32
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 31
- 229940068196 placebo Drugs 0.000 description 30
- 239000000902 placebo Substances 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 29
- 238000010790 dilution Methods 0.000 description 27
- 239000012895 dilution Substances 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 25
- 238000003556 assay Methods 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 241000710829 Dengue virus group Species 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 15
- 206010037660 Pyrexia Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 101000611764 Gordonia sp. (strain TY-5) Propane 2-monooxygenase, effector component Proteins 0.000 description 12
- 101001090095 Gordonia sp. (strain TY-5) Propane 2-monooxygenase, hydroxylase component large subunit Proteins 0.000 description 12
- 101001090278 Gordonia sp. (strain TY-5) Propane 2-monooxygenase, hydroxylase component small subunit Proteins 0.000 description 12
- 101000701089 Gordonia sp. (strain TY-5) Propane 2-monooxygenase, reductase component Proteins 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 101710204837 Envelope small membrane protein Proteins 0.000 description 10
- 101710145006 Lysis protein Proteins 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 210000003501 vero cell Anatomy 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 101100169272 Escherichia coli (strain K12) cydB gene Proteins 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 101100450407 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM1 gene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 108010084884 GDP-mannose transporter Proteins 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 239000004295 calcium sulphite Substances 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 201000009892 dengue shock syndrome Diseases 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 206010022095 Injection Site reaction Diseases 0.000 description 4
- 108091092724 Noncoding DNA Proteins 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000004293 potassium hydrogen sulphite Substances 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 101710085938 Matrix protein Proteins 0.000 description 3
- 238000007476 Maximum Likelihood Methods 0.000 description 3
- 101710127721 Membrane protein Proteins 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011976 chest X-ray Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- -1 E455 Substances 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000003623 Hypoalbuminemia Diseases 0.000 description 2
- 206010022086 Injection site pain Diseases 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229940124928 YF-Vax Drugs 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 208000020329 Zika virus infectious disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 239000004303 calcium sorbate Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035485 pulse pressure Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000011841 Abnormal homeostasis Diseases 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003791 Aura Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 101710128560 Initiator protein NS1 Proteins 0.000 description 1
- 206010022061 Injection site erythema Diseases 0.000 description 1
- 206010053425 Injection site swelling Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000001834 Lactylated fatty acid esters of glycerol and propane-1 Substances 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710144127 Non-structural protein 1 Proteins 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002856 computational phylogenetic analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568525P | 2017-10-05 | 2017-10-05 | |
| US62/568,525 | 2017-10-05 | ||
| PCT/IB2018/001219 WO2019069130A1 (en) | 2017-10-05 | 2018-10-05 | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536107A JP2020536107A (ja) | 2020-12-10 |
| JP2020536107A5 JP2020536107A5 (enExample) | 2021-11-11 |
| JP7313345B2 true JP7313345B2 (ja) | 2023-07-24 |
Family
ID=64184125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519400A Active JP7313345B2 (ja) | 2017-10-05 | 2018-10-05 | デング熱に対するブースターワクチン接種のための組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11690903B2 (enExample) |
| EP (1) | EP3691681A1 (enExample) |
| JP (1) | JP7313345B2 (enExample) |
| AU (1) | AU2018346724B2 (enExample) |
| SG (1) | SG11202002933TA (enExample) |
| WO (1) | WO2019069130A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691681A1 (en) * | 2017-10-05 | 2020-08-12 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
| WO2022123470A1 (en) * | 2020-12-10 | 2022-06-16 | Reagene Biosciences Pvt. Ltd. | Saliva based diagnostic assays for detection of sarscov2 receptor binding domain (rbd) neutralizing antibodies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015524421A (ja) | 2012-07-24 | 2015-08-24 | サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ | ワクチン組成物 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| PT977587E (pt) | 1997-02-28 | 2005-10-31 | Univ St Louis | Vacinas quimericas de flavivirus |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| CA2368790A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-3 virus vaccine |
| EP1165129A1 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-4 virus vaccine |
| CA2365728A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
| US6511667B1 (en) | 1999-03-26 | 2003-01-28 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-2 virus vaccine |
| WO2001039802A1 (en) | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Chimeric flavivirus vaccines |
| AU2001238441B2 (en) | 2000-02-16 | 2006-10-26 | Mahidol University | Avirulent, immunogenic flavivirus chimeras |
| EP1159968B1 (fr) | 2000-05-30 | 2008-10-29 | Mahidol University | Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| ES2523168T3 (es) | 2001-05-22 | 2014-11-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos |
| US7569383B2 (en) | 2001-06-01 | 2009-08-04 | Acambis Inc. | Chimeric flavivirus vectors |
| CA2473321C (en) | 2002-01-15 | 2015-10-06 | Acambis, Inc. | Flavivirus vaccines |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| WO2003101397A2 (en) | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
| WO2006134433A1 (en) | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
| WO2006134443A1 (en) | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
| WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
| EP1951865A4 (en) | 2005-11-21 | 2010-06-23 | Sanofi Pasteur Ltd | STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| US7968102B2 (en) | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| EP2117589A4 (en) | 2007-01-31 | 2010-07-21 | Sanofi Pasteur Biologics Co | FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS |
| BRPI0913012B1 (pt) | 2008-04-30 | 2021-12-14 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| AU2010277222A1 (en) | 2009-07-29 | 2012-03-08 | Bryce Malcolm Buddle | Polymer particles and uses thereof |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
| US8993744B2 (en) | 2010-05-21 | 2015-03-31 | University of Pittsburgh—of the Commonwealth System of Higher Education | Universal dengue virus sequences and methods of use |
| WO2012051491A1 (en) | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
| MX2015000446A (es) | 2012-07-24 | 2015-03-12 | Sanofi Pasteur | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue. |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| US10518409B2 (en) * | 2014-09-02 | 2019-12-31 | Mark Oleynik | Robotic manipulation methods and systems for executing a domain-specific application in an instrumented environment with electronic minimanipulation libraries |
| WO2017005654A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
| US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| EP3691681A1 (en) * | 2017-10-05 | 2020-08-12 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
-
2018
- 2018-10-05 EP EP18799824.0A patent/EP3691681A1/en active Pending
- 2018-10-05 WO PCT/IB2018/001219 patent/WO2019069130A1/en not_active Ceased
- 2018-10-05 JP JP2020519400A patent/JP7313345B2/ja active Active
- 2018-10-05 AU AU2018346724A patent/AU2018346724B2/en active Active
- 2018-10-05 US US16/652,902 patent/US11690903B2/en active Active
- 2018-10-05 SG SG11202002933TA patent/SG11202002933TA/en unknown
-
2023
- 2023-06-02 US US18/328,403 patent/US20230338504A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015524421A (ja) | 2012-07-24 | 2015-08-24 | サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ | ワクチン組成物 |
Non-Patent Citations (1)
| Title |
|---|
| GUY, B. et al，From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine，Vaccine，2011年，Vol.29，pp.7229-7241 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230338504A1 (en) | 2023-10-26 |
| SG11202002933TA (en) | 2020-04-29 |
| AU2018346724B2 (en) | 2025-01-09 |
| EP3691681A1 (en) | 2020-08-12 |
| WO2019069130A1 (en) | 2019-04-11 |
| AU2018346724A1 (en) | 2020-05-14 |
| US11690903B2 (en) | 2023-07-04 |
| JP2020536107A (ja) | 2020-12-10 |
| US20200289637A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI852899B (zh) | 疫苗組合物 | |
| TWI406673B (zh) | 對抗４種登革熱血清型之免疫方法 | |
| AU2013295014B2 (en) | Vaccine compositions | |
| US20150265695A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
| Tran et al. | Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children | |
| US20230338504A1 (en) | Compositions for Booster Vaccination Against Dengue | |
| Wright et al. | Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers | |
| JP2025032070A (ja) | デング熱及びａ型肝炎を予防するための方法 | |
| WO2014083194A1 (en) | Methods for inducing antibodies | |
| US12201683B2 (en) | Methods for preventing dengue and hepatitis a | |
| HK1242193A1 (en) | Vaccine compositions against dengue virus diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210930 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230526 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230613 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230711 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7313345 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |